Claims for Patent: 10,487,098

Summary for Patent: 10,487,098

Title:	Soluble C5aR antagonists
Abstract:	Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s):	Fan; Pingchen (Fremont, CA), Krasinski; Antoni (Sunnyvale, CA), Mali; Venkat Reddy (Cupertino, CA), Miao; Shichang (Foster City, CA), Punna; Sreenivas (Sunnyvale, CA), Song; Yang (Foster City, CA), Stella; Valentino J. (Lawrence, KS), Zeng; Yibin (Foster City, CA), Zhang; Penglie (Foster City, CA)
Assignee:	ChemoCentryx, Inc. (Mountain View, CA)
Application Number:	16/357,889
Patent Claims:	1. A method of inhibiting C5a binding in a human suffering from or susceptible to a disease or disorder, wherein the disease or disorder treatable by such inhibition include an inflammatory disease or disorder, an autoimmune disease or disorder, an oncologic disease or disorder, a cardiovascular disorder, or cerebrovascular disorder comprising administering to the mammal a therapeutically effective amount of Formula I or a pharmaceutical composition comprising a compound of Formula (I) ##STR00062## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of H, --O--CH.sub.2--O--P(O)OR.sup.aOR.sup.b, --O--C(O)--C.sub.1-6 alkylene-L.sup.2-X.sup.1, O--P(O)OR.sup.aOR.sup.b, and --O--C(O)-A.sup.1-(C.sub.1-3 alkylene).sub.n-C.sub.4-7 heterocyclyl wherein the C.sub.4-7 heterocyclyl is optionally substituted with 1 to 6 R.sup.c groups, A.sup.1 is selected from the group consisting of C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, C.sub.5-10 heteroaryl and C.sub.5-10 heterocyclyl, each of which is optionally substituted with 1 to 5 R.sup.x which can be the same or different; n=0 or 1; L.sup.2 is independently selected from the group consisting of a bond, --O--C(O)--C.sub.1-6alkylene-, and --NR.sup.d--C(O)--C.sub.1-6alkylene-; X.sup.1 is independently selected from the group consisting of --NR.sup.eR.sup.f, --P(O)OR.sup.aOR.sup.b, --O--P(O)OR.sup.aOR.sup.b, and --CO.sub.2H; R.sup.2 is selected from the group consisting of H, -L.sup.3-C.sub.1-6 alkylene-L.sup.4-X.sup.2, -L.sup.3-(C.sub.1-6 alkylene).sub.m-A.sup.2-X.sup.2, --P(O)OR.sup.aOC(O)--C.sub.1-6 alkyl, --P(O)OR.sup.aNR.sup.gR.sup.h and --P(O)OR.sup.aOR.sup.b, L.sup.3 is independently selected from the group consisting of --C(O)--O--, and --C(O)--; L.sup.4 is independently selected from the group consisting of a bond, --O--C(O)--C.sub.2-6alkenylene-, --O--C(O)--C.sub.1-6 alkylene-, and --NR.sup.d--C(O)--C.sub.1-6alkylene- wherein the C.sub.1-6 alkylene in --NR.sup.d--C(O)--C.sub.1-6alkylene- and --O--C(O)--C.sub.1-6alkylene- is optionally substituted with NR.sup.eR.sup.f; X.sup.2 is independently selected from the group consisting of --NR.sup.kR.sup.l, --P(O)OR.sup.aOR.sup.b, --O--P(O)OR.sup.aOR.sup.b, and --CO.sub.2H; m=0 or 1; A.sup.2 is selected from the group consisting of C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, C.sub.5-10 heteroaryl and C.sub.5-10 heterocyclyl, each of which is optionally substituted with 1 to 5 R.sup.x which can be the same or different; R.sup.3 is H or -L.sup.5-P(O)OR.sup.aOR.sup.b wherein L.sup.5 is independently selected from the group consisting of a bond and --CH.sub.2--O--; each R.sup.x is independently selected from the group consisting of halogen, C.sub.1-6alkyl, C.sub.1-6haloalkyl, C.sub.1-6heteroalkyl, CN, NR.sup.yR.sup.z, SR.sup.y and OR.sup.y; each R.sup.c is independently selected from the group consisting of halogen, C.sub.1-6alkyl, C.sub.1-6haloalkyl, C.sub.1-6heteroalkyl, CN, NR.sup.yR.sup.z, SR.sup.y and OR.sup.y; each R.sup.a, R.sup.b, R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.k, R.sup.l, R.sup.y and R.sup.z is independently selected from the group consisting of H and C.sub.1-6 alkyl; each R.sup.h is independently selected from the group consisting of H and C.sub.1-6 alkyl wherein the C.sub.1-6 alkyl is optionally substituted with 1 to 5 substituents independently selected from CO.sub.2H, NR.sup.iR.sup.j, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, C.sub.5-10 heteroaryl and C.sub.5-10 heterocyclyl, wherein each R.sup.i and R.sup.j is independently H or C.sub.1-6 alkyl; wherein two of R.sup.1, R.sup.2 and R.sup.3 are H, and one of R.sup.1, R.sup.2 and R.sup.3 is other than H. 2. The method of claim 1, wherein the disease or disorder is selected from the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease, membranoproliferative glomerulonephritis, Kawasaki disease, sepsis, septic shock, Hemolytic uremic syndrome, atypical hemolytic uremic syndrome (aHUS), Alzheimer's disease, multiple sclerosis, stroke, inflammatory bowel disease, chronic obstructive pulmonary disorder, inflammation associated with burns, lung injury, osteoarthritis, atopic dermatitis, chronic urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome, systemic inflammatory response syndrome, multiple organ dysfunction syndrome, Uveitis, tissue graft rejection, hyperacute rejection of transplanted organs, myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, polypoidal choroidal vasculopathy, traumatic central nervous system injury, ischemic heart disease, rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, ANCA vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, immuno vasculitis, Graft versus host disease, Paroxysmal nocturnal hemoglobinuria, Sjoegrens syndrome, insulin-dependent diabetes, mellitus, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, IGA nephropathy, Membranoproliferative glomerulonephritis, Antiphospholipid syndrome, Age related macular degeneration; Dry age related macular degeneration, Wet age related macular degeneration, Motor neurone disease, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces. 3. The method of claim 1, wherein the disease or disorder is selected from the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease, membranoproliferative glomerulonephritis, Kawasaki disease, Hemolytic uremic syndrome, atypical hemolytic uremic syndrome (aHUS), tissue graft rejection, hyperacute rejection of transplanted organs, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, lupus glomerulonephritis, vasculitis, ANCA vasculitis, autoimmune hemolytic and thrombocytopenic states, immuno vasculitis, Graft versus host disease, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, IGA nephropathy, Membranoproliferative and glomerulonephritis. 4. The method of claim 1, wherein the disease or disorder is selected from the group consisting of melanoma, lung cancer, lymphoma, sarcoma, carcinoma, fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synovioma, mesothelioma, meningioma, leukemia, lymphoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma and fibroma. 5. The method of claim 1, further comprising administering to the human a therapeutically effective amount of one or more additional therapeutic agents. 6. The method of claim 5, wherein the one or more additional therapeutic agents is selected from the group consisting of corticosteroids, steroids, immunosuppressants, Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors, Lymphocyte function antigen-3 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta ligand inhibitors, IL-2 receptor alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, Alpha 1 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone deacetylase inhibitors, AKT protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators, TNF antagonists, proteasome inhibitors, CD3 modulators, Hsp 70 family inhibitors, Immunoglobulin agonists, CD30 antagonists, tubulin antagonists, Sphingosine-1-phosphate receptor-1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors, adrenocorticotrophic hormone ligands, Btk tyrosine kinase inhibitors, Complement C1s subcomponent inhibitors, Erythropoietin receptor agonists, B-lymphocyte stimulator ligand inhibitors, Cyclin-dependent kinase-2 inhibitors, P-selectin glycoprotein ligand-1 stimulators, mTOR inhibitors, Elongation factor 2 inhibitors, Cell adhesion molecule inhibitors, Factor XIII agonists, Calcineurin inhibitors, Immunoglobulin G1 agonists, Inosine monophosphate dehydrogenase inhibitors, Complement C1s subcomponent inhibitors, Thymidine kinase modulators, Cytotoxic T-lymphocyte protein-4 modulators, Angiotensin II receptor antagonists, Angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52 antagonists, Adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors, CCR5 chemokine antagonists, CCR2 chemokine antagonists, Syk tyrosine kinase inhibitors, Interferon type I receptor antagonists, Interferon alpha ligand inhibitors, Macrophage migration inhibitory factor inhibitors, Integrin alpha-V/beta-6 antagonists, Cysteine protease stimulators, p38 MAP kinase inhibitors, TP53 gene inhibitors, Shiga like toxin I inhibitors, Fucosyltransferase 6 stimulators, Interleukin 22 ligands, CXCR1 chemokine antagonists, CXCR4 chemokine antagonists, IRS1 gene inhibitors, Protein kinase C stimulators, Protein kinase C alpha inhibitors, CD74 antagonists, Immunoglobulin gamma Fc receptor IIB antagonists, T-cell antigen CD7 inhibitors, CD95 antagonists, N acetylmannosamine kinase stimulators, Cardiotrophin-1 ligands, Leukocyte elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, Mannan-binding lectin serine protease-2 (MASP-2) inhibitors, Factor B inhibitors, Factor D inhibitors, and T cell receptor antagonists, and combinations thereof. 7. The method of claim 5, wherein the one or more additional therapeutic agent is selected from the group consisting of obinutuzumab, rituximab, ocrelizumab, cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998, immuglo, begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, inolimomab, beperminogene perplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod, panobinostat, triciribine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromonab, otelixizumab, gusperimus, brentuximab vedotin, Ponesimod, KRP-203, FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy polyethylene glycol-epoetin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukin diftitox, LMB-2, natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin, voclosporin, canakinumab, mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan medoxomil, sparsentan, TXA-127, alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011, losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74, cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-101, defibrotide, pomalidomide, Thymoglobulin, laquinimod, remestemcel-L, Equine antithymocyte immunoglobulin, Stempeucel, LIV-Gamma, Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg, Prosorba, pomalidomide, laquinimod, teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU, irbesartan+propagermanium, ApoCell, cannabidiol, RGI-2001, saratin, anti-CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-CCS, ACH-4471, AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells, and combinations thereof.

Details for Patent 10,487,098

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Iovance Biotherapeutics Manufacturing Llc	PROLEUKIN	aldesleukin	For Injection	103293	May 05, 1992		2036-04-04
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2036-04-04
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997		2036-04-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	May 12, 1998		2036-04-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	January 02, 2003		2036-04-04
Eisai, Incorporated	ONTAK	denileukin diftitox	Injection	103767	February 05, 1999		2036-04-04
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998		2036-04-04